Emily M. Leproust - 21 Nov 2025 Form 4 Insider Report for Twist Bioscience Corp (TWST)

Role: Chief Executive Officer, Director
Signature: /s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust
Issuer symbol: TWST
Transactions as of: 21 Nov 2025
Transactions value $: -$70,579
Form type: 4
Filing time: 25 Nov 2025, 16:05:16 UTC
Previous filing: 20 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Leproust Emily M.	Chief Executive Officer, Director	C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO	/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust	25 Nov 2025	0001753655

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TWST	Common Stock	Sale	-$70.6K	-2.66K	-0.3%	$26.50	878K	21 Nov 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TWST	Employee Stock Option (right to buy)						0	21 Nov 2025	Common Stock	0	$5.95	Direct	F2
holding	TWST	Employee Stock Option (right to buy)						151K	21 Nov 2025	Common Stock	0	$8.82	Direct	F3
holding	TWST	Employee Stock Option (right to buy)						267K	21 Nov 2025	Common Stock	0	$26.66	Direct	F4
holding	TWST	Employee Stock Option (right to buy)						131K	21 Nov 2025	Common Stock	0	$23.33	Direct	F5
holding	TWST	Employee Stock Option (right to buy)						65K	21 Nov 2025	Common Stock	65K	$67.85	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F2	The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F3	The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F4	20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F5	25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F6	Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.